Switch theme
Sign up to access all valuation multiples
Jiangsu Hengrui Pharmaceuticals Co Ltd is engaged in the field of cancer treatment drugs, surgical medicines, endocrine therapy drugs, cardiovascular drugs and anti-infection medications. It specializes in the research and development of new medicines in areas of antineoplastics, endocrine system, cardiovascular, and the immune system.
1997
3.9K+
LTM Revenue $4.0B
LTM EBITDA $1.0B
$46.8B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Jiangsu Hengrui has a last 12-month revenue (LTM) of $4.0B and a last 12-month EBITDA of $1.0B.
In the most recent fiscal year, Jiangsu Hengrui achieved revenue of $3.9B and an EBITDA of $1.1B.
Jiangsu Hengrui expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Jiangsu Hengrui valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $4.0B | XXX | $3.9B | XXX | XXX | XXX |
| Gross Profit | $3.5B | XXX | $3.4B | XXX | XXX | XXX |
| Gross Margin | 86% | XXX | 86% | XXX | XXX | XXX |
| EBITDA | $1.0B | XXX | $1.1B | XXX | XXX | XXX |
| EBITDA Margin | 26% | XXX | 28% | XXX | XXX | XXX |
| EBIT | $1.0B | XXX | $944M | XXX | XXX | XXX |
| EBIT Margin | 25% | XXX | 24% | XXX | XXX | XXX |
| Net Profit | $914M | XXX | $879M | XXX | XXX | XXX |
| Net Margin | 23% | XXX | 23% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Jiangsu Hengrui's stock price is CNY 55 (or $8).
Jiangsu Hengrui has current market cap of CNY 361B (or $50.1B), and EV of CNY 337B (or $46.8B).
See Jiangsu Hengrui trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $46.8B | $50.1B | XXX | XXX | XXX | XXX | $0.14 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Jiangsu Hengrui has market cap of $50.1B and EV of $46.8B.
Jiangsu Hengrui's trades at 12.0x EV/Revenue multiple, and 42.4x EV/EBITDA.
Equity research analysts estimate Jiangsu Hengrui's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Jiangsu Hengrui has a P/E ratio of 54.9x.
See valuation multiples for Jiangsu Hengrui and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $50.1B | XXX | $50.1B | XXX | XXX | XXX |
| EV (current) | $46.8B | XXX | $46.8B | XXX | XXX | XXX |
| EV/Revenue | 11.6x | XXX | 12.0x | XXX | XXX | XXX |
| EV/EBITDA | 45.3x | XXX | 42.4x | XXX | XXX | XXX |
| EV/EBIT | 46.0x | XXX | 49.5x | XXX | XXX | XXX |
| EV/Gross Profit | 13.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | 54.9x | XXX | 57.0x | XXX | XXX | XXX |
| EV/FCF | 66.8x | XXX | 61.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialJiangsu Hengrui's last 12 month revenue growth is 12%
Jiangsu Hengrui's revenue per employee in the last FY averaged $1.0M, while opex per employee averaged $0.6M for the same period.
Jiangsu Hengrui's rule of 40 is 36% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Jiangsu Hengrui's rule of X is 56% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Jiangsu Hengrui and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 12% | XXX | 12% | XXX | XXX | XXX |
| EBITDA Margin | 26% | XXX | 28% | XXX | XXX | XXX |
| EBITDA Growth | 13% | XXX | 21% | XXX | XXX | XXX |
| Rule of 40 | 36% | XXX | 41% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 56% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $1.0M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.6M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 20% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 24% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 62% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Jiangsu Hengrui acquired XXX companies to date.
Last acquisition by Jiangsu Hengrui was XXXXXXXX, XXXXX XXXXX XXXXXX . Jiangsu Hengrui acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Jiangsu Hengrui founded? | Jiangsu Hengrui was founded in 1997. |
| Where is Jiangsu Hengrui headquartered? | Jiangsu Hengrui is headquartered in China. |
| How many employees does Jiangsu Hengrui have? | As of today, Jiangsu Hengrui has 3.9K+ employees. |
| Is Jiangsu Hengrui publicy listed? | Yes, Jiangsu Hengrui is a public company listed on SHG. |
| What is the stock symbol of Jiangsu Hengrui? | Jiangsu Hengrui trades under 600276 ticker. |
| When did Jiangsu Hengrui go public? | Jiangsu Hengrui went public in 2000. |
| Who are competitors of Jiangsu Hengrui? | Similar companies to Jiangsu Hengrui include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Jiangsu Hengrui? | Jiangsu Hengrui's current market cap is $50.1B |
| What is the current revenue of Jiangsu Hengrui? | Jiangsu Hengrui's last 12 months revenue is $4.0B. |
| What is the current revenue growth of Jiangsu Hengrui? | Jiangsu Hengrui revenue growth (NTM/LTM) is 12%. |
| What is the current EV/Revenue multiple of Jiangsu Hengrui? | Current revenue multiple of Jiangsu Hengrui is 11.6x. |
| Is Jiangsu Hengrui profitable? | Yes, Jiangsu Hengrui is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Jiangsu Hengrui? | Jiangsu Hengrui's last 12 months EBITDA is $1.0B. |
| What is Jiangsu Hengrui's EBITDA margin? | Jiangsu Hengrui's last 12 months EBITDA margin is 26%. |
| What is the current EV/EBITDA multiple of Jiangsu Hengrui? | Current EBITDA multiple of Jiangsu Hengrui is 45.3x. |
| What is the current FCF of Jiangsu Hengrui? | Jiangsu Hengrui's last 12 months FCF is $701M. |
| What is Jiangsu Hengrui's FCF margin? | Jiangsu Hengrui's last 12 months FCF margin is 17%. |
| What is the current EV/FCF multiple of Jiangsu Hengrui? | Current FCF multiple of Jiangsu Hengrui is 66.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
